UroGen Pharma (URGN) Research & Development: 2016-2025
Historic Research & Development for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to $14.0 million.
- UroGen Pharma's Research & Development rose 23.36% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.7 million, marking a year-over-year increase of 26.39%. This contributed to the annual value of $57.1 million for FY2024, which is 25.28% up from last year.
- As of Q3 2025, UroGen Pharma's Research & Development stood at $14.0 million, which was down 25.94% from $18.9 million recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Research & Development ranged from a high of $19.9 million in Q1 2025 and a low of $10.2 million during Q3 2023.
- Over the past 3 years, UroGen Pharma's median Research & Development value was $14.0 million (recorded in 2025), while the average stood at $14.1 million.
- Per our database at Business Quant, UroGen Pharma's Research & Development fell by 26.91% in 2021 and then spiked by 32.96% in 2024.
- Quarterly analysis of 5 years shows UroGen Pharma's Research & Development stood at $13.1 million in 2021, then increased by 10.66% to $14.5 million in 2022, then declined by 21.93% to $11.3 million in 2023, then spiked by 31.78% to $14.9 million in 2024, then increased by 23.36% to $14.0 million in 2025.
- Its last three reported values are $14.0 million in Q3 2025, $18.9 million for Q2 2025, and $19.9 million during Q1 2025.